In this paper, we therefore studied a cohort of patients with inflammatory bowel diseases (IBD) who are being treated with antimetabolites (AM), TNF inhibitor (TNFi), and/or other biologic treatments (anti-integrin and anti-p40, and we characterized both cellular and humoral vaccine-induced spike-specific immunity. The gene discussed is TNF; the disease is inflammatory bowel disease.